(Q38366271)

English

Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long-Standing Model

scientific article published on 22 April 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

1 reference

Europe PubMed Central

Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long-Standing Model (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Parkinson's disease

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25726735%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25726735%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Anderson H F F Leão

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25726735%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Aldair J Sarmento-Silva

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25726735%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Alessandra M Ribeiro

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25726735%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

22 April 2015

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Brain Pathology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25726735%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25726735%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25726735%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

377-390

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25726735%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Effects of melatonin on orofacial movements in rats

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Vitamin E attenuates reserpine-induced oral dyskinesia and striatal oxidized glutathione/reduced glutathione ratio (GSSG/GSH) enhancement in rats.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Important role of striatal catalase in aging- and reserpine-induced oral dyskinesia.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Green tea modulates reserpine toxicity in animal models.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Age-related changes in metabolic responses to chronic monoamine depletion in central dopaminergic and serotonergic systems of rats treated with reserpine

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Predictors of dementia in Parkinson disease: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Environmental toxins and Parkinson's disease: putative roles of impaired electron transport chain and oxidative stress

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Possible involvement of oxido-nitrosative stress induced neuro-inflammatory cascade and monoaminergic pathway: underpinning the correlation between nociceptive and depressive behaviour in a rodent model.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Curcumin ameliorates reserpine-induced pain-depression dyad: behavioural, biochemical, neurochemical and molecular evidences

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Treatment of depressive symptoms in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Experimental models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Population-based case-control study of cognitive function in early Parkinson's disease (NEDICES).

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Alpha-lipoic acid differently affects the reserpine-induced oxidative stress in the striatum and prefrontal cortex of rat brain

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Comparative effects of Rauwolfia vomitoria and chlorpromazine on locomotor behaviour and anxiety in mice

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Classic and new animal models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

A mouse model of non-motor symptoms in Parkinson's disease: focus on pharmacological interventions targeting affective dysfunctions

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Staging of brain pathology related to sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Nociceptive brain activation in patients with neuropathic pain related to Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Research in motion: the enigma of Parkinson's disease pathology spread

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Effects of age on reserpine-induced orofacial dyskinesia and possible protection of diphenyl diselenide.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

A highly reproducible rotenone model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Effects of reserpine on the plus-maze discriminative avoidance task: dissociation between memory and motor impairments

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Industrial toxicants and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Animal models of neurological deficits: how relevant is the rat?

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Modelling of Parkinson's disease in mice

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

D1 and D2 dopamine binding site up-regulation and apomorphine-induced stereotypy

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Parallel PARKing: Parkinson's genes function in common pathway

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Learning processing in the basal ganglia: a mosaic of broken mirrors

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats?--case of amantadine and memantine

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Sex differences in dopamine- and vesicular monoamine-transporter functions

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Differences in reserpine-induced striatal dopamine output and content between female and male mice: implications for sex differences in vesicular monoamine transporter 2 function

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Olfactory dysfunction in incidental Lewy body disease and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Risk tables for parkinsonism and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Cognitive function in early Parkinson's disease: a population-based study

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Beneficial effects of vitamin C and vitamin E on reserpine-induced oral dyskinesia in rats: critical role of striatal catalase activity.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

A simple method to measure stride length as an index of nigrostriatal dysfunction in mice

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Memory impairment induced by low doses of reserpine in rats: possible relationship with emotional processing deficits in Parkinson disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Pain in Parkinson disease: a review of the literature

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Mental depression in hypertensive patients treated for long periods with large doses of reserpine.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Effects of ropinirole on various parkinsonian models in mice, rats, and cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Parkinson's disease: genetic versus toxin-induced rodent models

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Gene-environment interactions: key to unraveling the mystery of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Models of α-synuclein aggregation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

The effect of adenosine A(2A) receptor antagonists on hydroxyl radical, dopamine, and glutamate in the striatum of rats with altered function of VMAT2

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Oxidative stress and inflammation in Parkinson's disease: is there a causal link?

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Dopamine transporter (Dat) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Disease modification in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Postural changes after lesions of the substantia nigra pars reticulata in hemiparkinsonian monkeys.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

MPP(+)-induced toxicity in the presence of dopamine is mediated by COX-2 through oxidative stress

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

What has been learnt from study of dopamine receptors in Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Biological selectivity and functional aspects of protein tyrosine nitration

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

A systematic review of depression and mental illness preceding Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Locomotor hypokinesia in the reserpine-treated rat: drug effects from the corpus striatum and nucleus accumbens.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Disturbed sleep in Parkinson's disease: anatomical and pathological correlates

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Tardive dyskinesia: prevalence and risk factors, 1959 to 1979.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Parkinson's disease: clinical aspects

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Nitrotyrosine as a marker for peroxynitrite-induced neurotoxicity: the beginning or the end of the end of dopamine neurons?

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Catecholamine depletion by reserpine blocks the anxiolytic actions of ethanol in the rat.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Genetic factors involved in the pathogenesis of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Cognitive deficits in the early stages of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Attenuation of reserpine-induced pain/depression dyad by gentiopicroside through downregulation of GluN2B receptors in the amygdala of mice

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

The behavioural effects of pramipexole, a novel dopamine receptor agonist

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Microperoxisome distribution in the central nervous system of the rat

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Complexity of dopamine metabolism.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Animal models of Parkinson's disease progression

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Repeated reserpine administration up-regulates the transduction mechanisms of D1 receptors without changing the density of [3H]SCH 23390 binding.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Sleep disorders and daytime sleepiness in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Modeling dyskinesia in animal models of Parkinson disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Effect of Withania somnifera root extract on reserpine-induced orofacial dyskinesia and cognitive dysfunction

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: support for a model of tardive dyskinesia.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Meta-analysis of early nonmotor features and risk factors for Parkinson disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Reserpine causes biphasic nociceptive sensitivity alteration in conjunction with brain biogenic amine tones in rats

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

The real catecholamine content of secretory vesicles in the CNS revealed by electrochemical cytometry.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Enhanced sensitivity of dopaminergic neurons to rotenone-induced toxicity with aging

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Prodromal symptoms and early detection of Parkinson's disease in general practice: a nested case-control study

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Anxiety in Parkinson's disease: a critical review of experimental and clinical studies

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Computational systems analysis of dopamine metabolism

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

DJ-1 deficient mice demonstrate similar vulnerability to pathogenic Ala53Thr human alpha-syn toxicity

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Gallic acid decreases vacuous chewing movements induced by reserpine in rats.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

The Parkinson's disease-related genes act in mitochondrial homeostasis

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Dopaminergic contribution to the regulation of emotional perception

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Korean ginseng extract attenuates reserpine-induced orofacial dyskinesia and improves cognitive dysfunction in rats

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Cognitive, motor and tyrosine hydroxylase temporal impairment in a model of parkinsonism induced by reserpine.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Concomitant development of oral dyskinesia and memory deficits in reserpine-treated male and female mice

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Evaluation of the face validity of reserpine administration as an animal model of depression--Parkinson's disease association.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Chronic intraventricular administration of 1-methyl-4-phenylpyridinium as a progressive model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Actions of levodopa and dopamine in the central nervous system.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Dopamine turnover and glutathione oxidation: implications for Parkinson disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Deep brain stimulation of the substantia nigra pars reticulata improves forelimb akinesia in the hemiparkinsonian rat.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

The cellular pathology of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Influence of chronic exercise on reserpine-induced oxidative stress in rats: behavioral and antioxidant evaluations.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Intense exercise potentiates oxidative stress in striatum of reserpine-treated animals.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Acute reserpine treatment induces down regulation of D-1 dopamine receptor associated adenylyl cyclase activity in rat striatum

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

A guide to neurotoxic animal models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Tyrosine hydroxylase-like (TH) immunoreactivity in Parkinson's disease and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Reserpine-induced up-regulation of dopamine D2 receptors in the rat striatum is enhanced by denervation but not by chronic receptor blockade

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Spinal cord lesions in sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Environmental-genetic interactions in the pathogenesis of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Pain perception in patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Pharmacological profiles of three new, potent and selective dopamine receptor agonists: N-0434, N-0437 and N-0734.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Programmed cell death in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Is there a pathogenic role for mitochondria in Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Impulse control disorders in Parkinson's disease: recent advances

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Understanding the molecular causes of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Positive immunoreactivity for vesicular monoamine transporter 2 in Lewy bodies and Lewy neurites in substantia nigra

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+).

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Variable effects of chronic subcutaneous administration of rotenone on striatal histology

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

The locus ceruleus and dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Dopamine Affects the Stability, Hydration, and Packing of Protofibrils and Fibrils of the Wild Type and Variants of α-Synuclein†

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Neuropeptide S counteracts 6-OHDA-induced motor deficits in mice

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Mechanism of Hypotensive Action of Reserpine, an Alkaloid of Rauwolfia serpentina

1 reference

https://api.crossref.org/works/10.1111%2FBPA.12253

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38366271&oldid=2139534738"